乙肝表面抗原阳性肺结核患者抗结核治疗肝功损害研究  

STUDY OF LIVER FUNCTION IMPAIRMENT CAUSED BY ANTI -TUBERCULOSIS TREATMENT IN CASES OF POSITIVE HBSAG

作　　者：江堤 扬光 罗万蓉 

机构地区：[1]德阳市医院感染科,德阳618000

出　　处：《现代预防医学》2010年第17期3347-3348,3356,共3页Modern Preventive Medicine

摘　　要：[目的]观察抗结核药物对乙肝表面抗原阳性肺结核患者肝功能的影响,[方法]比较乙肝表面抗原阳性和阴性肺结核患者抗结核治疗肝功能损害的情况,并对其中HBV-DNA阳性肺结核患者抗结核联合口服阿德福韦酯抗病毒治疗进行疗效观察。[结果]乙肝表面抗原阳性患者肝损率比阴性者明显增高,其中HBV-DNA阳性肺结核患者抗结核联合口服阿德福韦酯抗病毒治疗,较之单纯护肝效果更佳。[结论]抗结核药物致肝损害的乙肝表面抗原阳性患者肝损率较阴性者高,对其中转氨酶升高的HBV-DNA阳性肺结核患者,抗结核联合口服阿德福韦酯抗病毒治疗有助于肝功恢复,进而有助于完成抗结核全疗程。[Objective] To study of liver function impairment caused by drug treating tuberculosis in cases of positive HBsAg. [Methods] Comparing liver function impairment in cases of positive HBsAg and negative HBsAg with anti-tuberculosis drug, and observed curative effect of anti-tuberculosis combined with Adefovir in treating cases of positive HBsAg. [Results] The severity of liver function impairment of positive HBsAg cases increased compared with negative HBsAg cases. The effect of anti-tuberculosis combined with Adefovir was better than the single method for protecting liver. [Conclusion] The severity of liver function impairment of positive HBsAg cases increases compared with negative HBsAg cases. For positive HBV-DNA cases, the united use of anti-tuberculosis drug and Adefovir benefits the entire course of treatment.

关 键 词：肺结核 乙肝表面抗原 HBV-DNA 肝功损害 

分 类 号：R512.62[医药卫生—内科学] R521[医药卫生—临床医学]